| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/13/2008 | US20080063660 inducing specific anti-drug antibodies using drug conjugated immunogen (bacterial toxoid) to reduce a drug's toxicity; drug is cocaine, nicotine, heroin, opium, morphine, marijuana, or antineoplastic; immunogen induces production of antibodies which sequester a subsequently administered drug; drug abuse |
| 03/13/2008 | US20080063657 antigen and flagellin which lacks a hinge region; antigen and flagellin are components of a fusion protein; pathogen-associated molecular pattern (PAMP) and a flavivirus; West Nile, Langat, Kunjin, Murray Valley encephalitis, Japanese encephalitis, Tick-borne encephalitis, Yellow fever viral proteins |
| 03/13/2008 | US20080063656 Adenoviral Vector Compositions |
| 03/13/2008 | US20080063655 nucleic acid sequences encoding a 30 kD Brachyspira hyodysenteriae lipoprotein; host cell; new locus comprising four genes has now surprisingly been found; swine dysentery |
| 03/13/2008 | US20080063654 Prostate Cancer Vaccine |
| 03/13/2008 | US20080063653 vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers; nucleic acid; agonist polypeptide derived from a mucin tumor antigen; genetic vaccine |
| 03/13/2008 | US20080063652 co-culture of hematopoietic progenitor cells and lymphoreticular stromal cells in a porous solid scaffold, resulting in unexpectedly high numbers of regulatory T cells |
| 03/13/2008 | US20080063651 therapeutic protein comprising a tenth domain of fibronectin type III; protein scaffold; antibody design; scaffold derived from a fibronectin type III (Fn3) or Fn3-like domain, function like natural or engineered antibodies; antibody mimics designed for optimal folding, stability, and solubility |
| 03/13/2008 | US20080063650 membrane-bound complement regulatory protein; use in enhancing the activity of antiproliferative/beta-glucan immunotherapy; mCRP antagonist; a therapeutic ligand capable of activating complement; and beta-glucan |
| 03/13/2008 | US20080063649 pretreatment step involving a highly specific and high affinity neutralizing antibody |
| 03/13/2008 | US20080063648 immunization against proliferative enteritis, known as ileitis |
| 03/13/2008 | US20080063647 Antibodies against protective antigen and methods of use for passive immunization and treatment of anthrax |
| 03/13/2008 | US20080063646 variable heavy chain amino acid sequence of SEQ ID NO. 50 and a variable light chain amino acid sequence of SEQ ID NO. 48, designated herein as HuAIP12 |
| 03/13/2008 | US20080063645 Endotoxin-adsorbent for the prevention and treatment of autoimmune diseases |
| 03/13/2008 | US20080063644 immunohistochemistry; skin thickening caused by ultraviolet treated by using the antibody; inhibit production of IFN-.gamma; promoting keratinocyte differentiation induction and suppressing epidermal thickening, skin cancer; inhibiting growth of keratinocytes; promotes hair growth; hyperplasia |
| 03/13/2008 | US20080063643 HLA-binding motif in its sequence; recognized by an HLA-A2- or HLA-A24-restricted cytotoxic T cell; nucleotide; antibody; vector; diagnosid and prognosis of hepatitis C virus infection |
| 03/13/2008 | US20080063642 Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders |
| 03/13/2008 | US20080063641 Comprise a single antigen binding arm and an Fc region; exhibits enhanced stability in vivo compared to a Fab antibody fragment |
| 03/13/2008 | US20080063640 Pin-Prc Transition Genes |
| 03/13/2008 | US20080063639 Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies |
| 03/13/2008 | US20080063638 Mitotic kinesin-like protein-1, MKLP1, and uses therof priority |
| 03/13/2008 | US20080063637 Regulation of oncogenesis by Akt-specific isoforms |
| 03/13/2008 | US20080063636 polypeptides having deletions in the amino acid sequence, useful as antigens for improving vaccine therapy; treatment of Alzheimer's disease |
| 03/13/2008 | US20080063635 Stabilized Human Igg4 Antibodies |
| 03/13/2008 | US20080063634 genetic engineered antibody or antigen binding segment that is capable of binding to interleukins and altering the conformation structure, used for treating diseases involving immune and inflammatory responses |
| 03/13/2008 | US20080063633 Fusion proteins comprising single chain FV fragment of an antibody, and transport proteins, used for treatment of skin cancer |
| 03/13/2008 | US20080063626 Minimization of drug oxidation in drug irradiated excipients formulations |
| 03/13/2008 | US20080063623 adjuvants comprising proteins, polynucleotides, or genetic vectors and carriers |
| 03/13/2008 | US20080063600 use of deactivated lymphocytes, antibodies, drug mixtures and adjuvants, for the treatment or prevention of Cruetzfield-Jacobs disease in humans or animals; immunology; bioassays |
| 03/13/2008 | US20080063598 chimeric antibodies, fragments, polypeptides and derivatives that preferentially bind tumor associated antigens (AF-20), useful in the treatment and diagnosis of cancers |
| 03/13/2008 | CA2698583A1 Cancer stem cell-targeted cancer therapy |
| 03/13/2008 | CA2663388A1 Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| 03/13/2008 | CA2663042A1 Serum albumin binding proteins with long half-lives |
| 03/13/2008 | CA2662707A1 Split-core-particles for the presentation of foreign molecules, especially for vaccine applications, and method for their production |
| 03/13/2008 | CA2662350A1 Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
| 03/13/2008 | CA2662340A1 Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 03/13/2008 | CA2662226A1 Fully human high yield production system for improved antibodies and proteins |
| 03/13/2008 | CA2662064A1 Method of producing a combination polivirus vaccine |
| 03/13/2008 | CA2662051A1 Vaccine |
| 03/13/2008 | CA2661923A1 Methods for blocking the interaction between nkp80 and its ligand aicl |
| 03/13/2008 | CA2661878A1 Anti-activin a antibodies and uses thereof |
| 03/13/2008 | CA2661836A1 Anti-myostatin antibodies |
| 03/13/2008 | CA2661645A1 Arginine wash in protein purification using affinity chromatography |
| 03/13/2008 | CA2661280A1 Mucosal and systemic adjuvants comprising glycolipids,corresponding conjugates and pharmaceutical compositions. |
| 03/13/2008 | CA2653696A1 Recombinant vaccine against bluetongue virus |
| 03/12/2008 | EP1897949A2 Human interleukin-B50. Therapeutic uses |
| 03/12/2008 | EP1897948A1 Mammalian transforming growth factor beta 9 |
| 03/12/2008 | EP1897947A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897946A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897945A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897944A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897943A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897887A1 Split-core-particles for the presentation of foreign molecules, especially for vaccination purposes and methods for their preparation |
| 03/12/2008 | EP1897557A1 Use of glycolipids as adjuvants |
| 03/12/2008 | EP1897556A1 Prevention and treatment of hypergastrinemia |
| 03/12/2008 | EP1897555A2 Supplemented OMV vaccine against meningococcus |
| 03/12/2008 | EP1897553A1 Inhibitor of stem cell proliferation and uses thereof |
| 03/12/2008 | EP1897548A1 T cell regulation |
| 03/12/2008 | EP1897538A1 Formulations for antigen-specific tolerance induction |
| 03/12/2008 | EP1896849A2 Antibodies against histone modifications for clinical diagnosis and prognosis of cancer |
| 03/12/2008 | EP1896589A2 Novel genes and proteins of brachyspira pilosicoli and use of same for diagnosis and therapy |
| 03/12/2008 | EP1896588A1 NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF |
| 03/12/2008 | EP1896507A2 Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells |
| 03/12/2008 | EP1896505A2 Anti-igf1r antibody formulations |
| 03/12/2008 | EP1896503A2 Igg1 antibodies with mutated fc portion for increased binding to fcrn receptor and uses tehereof |
| 03/12/2008 | EP1896494A2 Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| 03/12/2008 | EP1896073A2 Anti-il-23 antibodies, compositions, methods and uses |
| 03/12/2008 | EP1896072A2 A direct drug delivery system based on thermally responsive biopolymers |
| 03/12/2008 | EP1896071A2 Methods and compositions with enhanced therapeutic activity |
| 03/12/2008 | EP1896069A2 Inactivated chimeric vaccines and related methods of use |
| 03/12/2008 | EP1896068A1 Antigen conjugates and uses thereof |
| 03/12/2008 | EP1896067A2 Vaccines for immunization against helicobacter |
| 03/12/2008 | EP1896066A2 Immunogenic composition |
| 03/12/2008 | EP1896065A2 Process for manufacturing vaccines |
| 03/12/2008 | EP1896064A2 Immunogenic composition |
| 03/12/2008 | EP1896063A1 Immunogenic composition |
| 03/12/2008 | EP1896062A1 Immunogenic composition |
| 03/12/2008 | EP1896061A2 Immunogenic composition |
| 03/12/2008 | EP1896060A1 Anti-malaria vaccine |
| 03/12/2008 | EP1896053A1 Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use |
| 03/12/2008 | EP1895947A2 Improved method of treating degenerative spinal disorders |
| 03/12/2008 | EP1668031B1 Homogeneous preparations of il-29 |
| 03/12/2008 | EP1578791B1 Inclusion bodies for the oral vaccination of animals |
| 03/12/2008 | EP1537872A4 Immunostimulator having antineoplastic action and method for producing said immunostimulator |
| 03/12/2008 | EP1366367B1 Organ transplant rejection and associated conditions |
| 03/12/2008 | EP1278855B1 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 03/12/2008 | EP1210434B1 Mammalian interleukin-12 p40 and interleukin b30. combinations thereof. antibodies. uses in pharmaceutical compositions |
| 03/12/2008 | EP0972048B1 Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines |
| 03/12/2008 | EP0876487B1 Mammalian cx3c chemokine genes |
| 03/12/2008 | EP0614374B2 MURINE MONOCLONAL ANTIBODY (5c8) RECOGNIZES A HUMAN GLYCOPROTEIN ON THE SURFACE OF T-LYMPHOCYTES |
| 03/12/2008 | CN101142321A Methods and compositions for treating ocular disorders |
| 03/12/2008 | CN101142319A Vaccines based on the use of mv |
| 03/12/2008 | CN101142236A Adam-9调节剂 Adam-9 modifiers |
| 03/12/2008 | CN101142230A Yersinia spp. polypeptides and methods of use |
| 03/12/2008 | CN101141981A Fixed dosing of her antibodies |
| 03/12/2008 | CN101141980A Antibodies against human interleukin-13 and uses therefor |
| 03/12/2008 | CN101141979A Cat allergen conjugates and uses thereof |
| 03/12/2008 | CN101141978A Pharmaceutical preparation that can be administered orally for treating fish, production method for said preparation and use of the latter |
| 03/12/2008 | CN101141974A Protein introducing carrier, protein introducing agent given by using the carrier, method for introducing the protein, protein introduced cell, and method for producing the cell |
| 03/12/2008 | CN101141955A Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors |